Literature DB >> 22449624

Lymphoproliferative disorders associated with hypereosinophilia.

Florence Roufosse1, Soizic Garaud, Laurence de Leval.   

Abstract

Hypereosinophilia, defined as peripheral blood eosinophil counts > 1,500/μL, may complicate the course of various lymphoproliferative disorders. Among these, Hodgkin lymphoma (HL) and certain peripheral T-cell lymphomas (PTCLs) derived from CD4 cells, including Sezary syndrome (SS), adult T-cell leukemia/lymphoma (ATLL), and angioimmunoblastic T-cell lymphoma (AITL), are most commonly associated with increased reactive eosinophilopoiesis. Rarely, marked hypereosinophilia (HE) may occur in the setting of acute B-cell lymphoblastic leukemia, with a substantial impact on disease course. The mechanisms leading to blood and tissue eosinophilia in the setting of lymphoproliferative disorders, as well as the clinical complications and prognostic implications of hypereosinophilia, are discussed in this review.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22449624     DOI: 10.1053/j.seminhematol.2012.01.003

Source DB:  PubMed          Journal:  Semin Hematol        ISSN: 0037-1963            Impact factor:   3.851


  8 in total

Review 1.  Biologic Agents for the Treatment of Hypereosinophilic Syndromes.

Authors:  Fei Li Kuang; Amy D Klion
Journal:  J Allergy Clin Immunol Pract       Date:  2017 Nov - Dec

2.  CD3-CD4+ lymphoid variant of hypereosinophilic syndrome: nodal and extranodal histopathological and immunophenotypic features of a peripheral indolent clonal T-cell lymphoproliferative disorder.

Authors:  Guillaume Lefèvre; Marie-Christine Copin; Christophe Roumier; Hélène Aubert; Martine Avenel-Audran; Nathalie Grardel; Stéphanie Poulain; Delphine Staumont-Sallé; Julien Seneschal; Gilles Salles; Kamel Ghomari; Louis Terriou; Christian Leclech; Chafika Morati-Hafsaoui; Franck Morschhauser; Olivier Lambotte; Félix Ackerman; Jacques Trauet; Sandrine Geffroy; Florent Dumezy; Monique Capron; Catherine Roche-Lestienne; Alain Taieb; Pierre-Yves Hatron; Sylvain Dubucquoi; Eric Hachulla; Lionel Prin; Myriam Labalette; David Launay; Claude Preudhomme; Jean-Emmanuel Kahn
Journal:  Haematologica       Date:  2015-02-14       Impact factor: 9.941

Review 3.  Eosinophilia in Hematologic Disorders.

Authors:  Lorenzo Falchi; Srdan Verstovsek
Journal:  Immunol Allergy Clin North Am       Date:  2015-08       Impact factor: 3.479

4.  CD30 on extracellular vesicles from malignant Hodgkin cells supports damaging of CD30 ligand-expressing bystander cells with Brentuximab-Vedotin, in vitro.

Authors:  Hinrich P Hansen; Ahmad Trad; Maria Dams; Paola Zigrino; Marcia Moss; Maximilian Tator; Gisela Schön; Patricia C Grenzi; Daniel Bachurski; Bruno Aquino; Horst Dürkop; Katrin S Reiners; Michael von Bergwelt-Baildon; Michael Hallek; Joachim Grötzinger; Andreas Engert; Adriana F Paes Leme; Elke Pogge von Strandmann
Journal:  Oncotarget       Date:  2016-05-24

5.  Transcriptome analysis of Sézary syndrome and lymphocytic-variant hypereosinophilic syndrome T cells reveals common and divergent genes.

Authors:  Andrea M Moerman-Herzog; Daniel A Acheampong; Amanda G Brooks; Suzan M Blair; Ping-Ching Hsu; Henry K Wong
Journal:  Oncotarget       Date:  2019-08-20

6.  Clonal Hypereosinophilia with ETV6 Rearrangement Evolving to T-Cell Lymphoblastic Lymphoma: A Case Report and Review of the Literature.

Authors:  Filipa Moita; Isabel Bogalho; Helena Alaiz; Joana Parreira; Maria Jesus Frade; Albertina Nunes; Maria Gomes da Silva
Journal:  Case Rep Hematol       Date:  2013-04-21

7.  Induction of malignant plasma cell proliferation by eosinophils.

Authors:  Tina W Wong; Hirohito Kita; Curtis A Hanson; Denise K Walters; Bonnie K Arendt; Diane F Jelinek
Journal:  PLoS One       Date:  2013-07-22       Impact factor: 3.240

Review 8.  Gene Expression Comparison between Sézary Syndrome and Lymphocytic-Variant Hypereosinophilic Syndrome Refines Biomarkers for Sézary Syndrome.

Authors:  Andrea Moerman-Herzog; Syed J Mehdi; Henry K Wong
Journal:  Cells       Date:  2020-08-29       Impact factor: 6.600

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.